Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

More Problems At J & J Subsidiary

By Drug Discovery Trends Editor | August 26, 2010

TRENTON, N.J. (AP) – Johnson & Johnson’s artificial joint business is recalling two hip replacement products, just two days after getting hit with a government warning that it is illegally marketing two other products. It is the 11th J&J recall since September.

DePuy Orthopaedics Inc. said Thursday it is recalling two hip replacement products because new data, about to be released, show higher-than-expected rates of patients needing a second hip replacement procedure.

Within five years, one in eight patients needed a revision surgery. That’s required when an artificial joint doesn’t fit perfectly, causing pain and difficulty walking. The products are the ASR Hip Resurfacing System and the ASR XL Acetabular System.

“We are committed to assisting patients and healthcare providers by providing information through multiple channels and paying for the cost of doctor visits, tests and procedures associated with the recall,” David Floyd, president of DePuy Orthopaedics in Warsaw, Ind., said in a statement.

That includes monitoring of how well a patient’s hip is working and paying for any corrective surgery. Products still on hospitals shelves will be removed, said DePuy spokeswoman Lorie Gawreluk.

Each of the metal systems is used to replace a worn or weakened part of the hip, which consists of a socket at the outer edge of the pelvis and a rounded bone atop the thigh bone that fits into that socket like a ball. Total hip replacement involves replacing both parts at once.

The ASR Hip Resurfacing System replaces the ball portion of the hip and has a metal stem that fits into the top of the hip bone, or femur. The ASR XL Acetabular System is a concave metal piece used to provide a smooth lining for the acetabulum, the bowl-shaped socket in the pelvis.

DePuy, part of Johnson & Johnson of New Brunswick, N.J., said data it received from the National Joint Registry of England and Wales shows that within five years, about 12 percent of people getting the hip resurfacing system and about 13 percent of those getting the acetabular system needed corrective surgery. Women were more likely to need a second surgery than men.

DePuy said previous data “had shown lower revision rates and that the ASR hip was performing in line with other devices in its class.”

Gawreluk said she did not have the actual numbers of patients with problems.

The acetabular system, launched in 2004, has been sold worldwide. The resurfacing system, introduced in 2003, is only sold outside the U.S.

DePuy decided last fall to discontinue both, Gawreluk said. The company is working on developing a new generation of both products.

On Tuesday, the Food and Drug Administration told DePuy to stop selling its Corail Hip System for two unapproved uses. It also ordered the company to provide information needed to review another product the agency said DePuy has been selling even though it was never approved. It’s called the TruMatch Personalized Solution System, and uses software and high-tech CT scanning technology to create a 3-D view of a patient’s knee to help a surgeon position a knee implant.

On Monday, Johnson & Johnson recalled millions of 1 Day Acuvue TruEye contact lenses sold in Asia and Europe because some users complained of stinging or pain when they inserted the lenses.

Johnson & Johnson remains under scrutiny by the FDA, Congress and federal prosecutors over eight previous U.S. recalls of nonprescription medicines since last September. Those included millions of bottles of Tylenol, other pain relievers and cold medicines for children and adults, for problems including bacterial contamination and tiny metal savings found in some bottles.

Date: August 26, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE